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Summary
Objective: To assess the reliability, validity and responsiveness of the Australian/Canadian (AUSCAN) Osteoarthritis Hand Index in both
Likert (LK) and Visual Analogue (VA)-scaled formats.
Methods: Two separate studies were conducted; the first addressing reliability and validity issues and the second addressing index
responsiveness. In a group of 50 patients with osteoarthritis (OA) of the hand, test–retest reliability was assessed at a 1-week interval and
internal consistency from single administrations of the Index. Construct validity was evaluated against several other outcome measures
including the Functional Index for Hand Osteoarthritis (FIHOA), separate patient and physician global assessments, Doyle Index, grip
strength, pinch grip, and Health Assessment Questionnaire. A 6-week washout retreatment design was used in a group of 44 OA hand
patients to assess index responsiveness and comparative responsiveness against the FIHOA.
Results: Reliability and construct validity coefficients confirm the reliability and construct validity of both the AUSCAN LK3.0 and AUSCAN
VA3.0 Indices. The washout retreatment study establishes index responsiveness and suggests that the AUSCAN LK3.0 and AUSCAN VA3.0
Indices may be more responsive than the FIHOA.
Conclusions: The patient self-completed AUSCAN LK3.0 and AUSCAN VA3.0 Indices are reliable, valid and responsive and can be
recommended as primary outcome measures for future hand OA clinical trials. © 2002 OsteoArthritis Research Society International.
Published by Elsevier Science Ltd. All rights reserved.
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The main objective of evaluative research is to detect
differential change in two or more treatment groups
exposed to different interventions1. The outcome instru-
ments employed to detect change require simultaneously
to be valid, reliable2,3 and responsive (syn: sensitive). Of
these three clinimetric properties responsiveness is of
paramount importance for evaluative measures4. Recently,
the current definitions of, and criteria for, hand osteoarthritis
(OA), and the tools proposed for the clinical assessment of
hand OA in research and trials, have been reviewed5,6. A
critical review of therapeutic trials in hand OA has also been863performed7. Following the consensus agreement method-
ology used by the Osteoarthritis Research Society
International (OARSI) for establishing guidelines for the
design and conduct of clinical trials in patients with OA of
the knee and hip8,9, consideration is being given currently
to establishing guidelines for the conduct of trials in hand
OA10.
In an attempt to rationalize measurement in OA of the
hand, we first probed the symptomatology of hand OA by
interviewing 50 patients with OA, and subsequently ident-
ified 39 items on three dimensions (e.g., pain (10), stiffness
(2), physical function (27)) which characterized the
clinical expression of the disorder and defined the clinical
importance of each11,12.
We subsequently segmented these items into a group of
5 pain, 1 stiffness and 9 physical function ‘candidate’ items
for potential inclusion in the AUSCAN Index, and a second
group of 5 pain, 1 stiffness and 18 physical function
‘reserve’ items, for addressing a methodologic issue relat-
ing to early vs late item reduction in index construction,
which we will report under separate cover at a later date.
The study reported here concerns the 5 pain, 1 stiffness
and 9 physical function candidate items for inclusion in the
864 N. Bellamy et al.: AUSCAN OA Hand Index clinimetric propertiesMaterial and methods
STUDY 1: VALIDITY AND RELIABILITY STUDYPatients
To be eligible patients had to fulfill the following criteria:
age 30–80 years, fluent in the English language, fulfill the
American College of Rheumatology clinical criteria for OA
hand18, have symptomatic (i.e. pain or disability) OA of the
hand (DIP and/or PIP and/or CMC±MCP and/or wrist
involvement), and be willing to provide informed consent.
Any patient who had prior orthopaedic surgery on the hand
joints, psoriasis or rheumatoid arthritis was excluded.
Ethics approval was obtained from the Review Board for
Health Sciences Research Involving Human Subjects, The
University of Western Ontario and the Ethics Committee on
Research, The Royal Melbourne Hospital.Validity
In order to test the construct validity of AUSCAN, the
following outcome measures were studied: grip strength
(mm Hg) and pinch grip (kg) (average of three attempts
bilaterally using a standardized method), modified Doyle
Index [i.e., tenderness at DIP, PIP, MCP, thumb and wrist
scored 0, 1, 2 or 3 (Ritchie scores)], and physician global
assessment of symptom severity in the hand (Question:
‘How would you rate the overall severity of the patient’s
hand symptoms in the last 48 hours?’), scored on a 5-point
categorical scale (i.e., none, mild, moderate, severe and
extreme). These measures were made by one of two
rheumatologists (NB or ES). Patients were asked to indi-
cate their global assessment of hand pain (Question:
‘Please indicate the overall severity of pain experienced in
your hands in the last 48 hours.’) and global assessment
of hand function (Question: ‘Please indicate the overall
severity of physical disability experienced in your hands in
the last 48 hours.’). Both of these global assessments were
scored on the same five-point categorical scale as the
physician global assessment. Duration of morning stiffness
in the hands was also ascertained by patient interview.
Patients completed, in random order, both the Likert-
scaled19 and visual analogue-scaled (VAS) formats of
the AUSCAN. Patients were then asked to complete the
English version of the FIHOA20–22. Since we were inter-
ested in scaling issues relating to the FIHOA, in addition to
original format (0–3), we also presented rescaled Likert
(0–4) and VA (0–100 mm) formats of the FIHOA to patients.
The original format was presented first followed by the VA
and Likert formats, in random order, but in the same order
as the AUSCAN, which was completed before the FIHOA.
The Health Assessment Questionnaire (HAQ) and the HAQ
pain scale were also completed23.
Finally, patients were asked to complete the Patient
Assessment of the Relative Importance of Symptoms
(PARIS) Sectogram24,25, a method of weighting the three
dimensions of pain, stiffness, and function contained in the
AUSCAN Index. The PARIS Sectogram data analysis will
be reported in a future publication.
Patients were assessed at two points in time, 1 week
apart, resulting in two determinations of construct validity.Reliability
Patients were assessed at two points in time, 1 week
apart, in order to address test–retest issues. At the second
assessment patients completed both forms of the AUSCAN
Index. This allowed one determination of test–retest
reliability but two determinations of internal consistency.Table I
Summary of item content of AUSCAN12
Item Mean importance score
Pain
1 Rest 1.95
2 Gripping 2.34
3 Lifting 2.47
4 Turning 2.30
5 Squeezing 2.36
Stiffness
1 Morning 2.06
Physical function
1 Turning taps/faucets on 2.05
2 Turning doorknob/handle 1.97
3 Doing up buttons 2.33
4 Fastening jewellery 1.97
5 Opening a new jar 2.43
6 Carrying full pot one hand 2.43
7 Peeling vegetables/fruit 2.48
8 Picking up large heavy objects 2.43
9 Wringing out washcloths 2.50
Mean importance score (MIS) previously published12 (Scale:
0=none, 1=slight, 2=moderate, 3=very, 4=extreme importance;
MIS=sum of the individual importance scores given by N affected
patients divided by N).Data analysis
Disease (duration and ACR functional class26) and
demographic (age, gender, handedness) profiles are
reported using descriptive statistics. Test–retest reliability
was tested using intraclass correlation coefficient calcu-
lated on a two-way mixed effect model (e.g. time fixed,
rater random). Internal consistency of the pain and func-
tion subscales was assessed by Cronbach’s alpha27. Con-
struct validity was determined using both Pearson’s and
Spearman’s correlation coefficients28.AUSCAN Index (Table I)11–14. All 15 items probe symptom
severity in different commonly experienced situations. Our
goal was to assess the reliability, construct validity, and
responsiveness of these 15 items.
In addition to defining the three main clinimetric proper-
ties of the AUSCAN Index, we have also examined issues
relating to scaling, employing a similar framework to
that previously used in the development of the WOMAC
Osteoarthritis Index15–17. The report that follows encom-
passes the results of two separate studies: the first, a study
of the reliability and validity of the AUSCAN, and the
second, a study of the responsiveness of the AUSCAN.
The resulting health status measure has been termed the
AUSCAN 3.0 Osteoarthritis Hand Index, and is available in
either Likert-scaled format (AUSCAN LK3.0) or visual
analogue-scaled format (AUSCAN VA3.0).
Osteoarthritis and Cartilage Vol. 10, No. 11 865STUDY 2: RESPONSIVENESS STUDYPatients
To be eligible patients had to fulfill the same criteria used
in Study 1, with the following exception. Fluency in English
was not an inclusion criterion since we included patients
whose mother language was French Canadian. In addition,
patients had to be taking a non-steroidal antiinflammatory
drug (NSAID).Method
The therapeutic manoeuvre used to assess responsive-
ness was to discontinue the patient’s current NSAID for
several days (i.e. washout), and then to restart the same
NSAID (i.e. retreatment), in order to observe the subse-
quent response. In particular, patients were asked to dis-
continue their current NSAID for 3–7 days, during which
time they were permitted to take acetaminophen on an ‘as
required basis’. Washout periods varying from 3–7 days in
duration often have been utilized in OA clinical trials
reported in the literature29. While the limits are arbitrary,
based on prior experience, we consider a minimum of
3 days is required to produce a flare in symptoms and the
upper limit of 7 days reflects concern to limit the period
of patient discomfort necessary to achieve a flare in
symptoms. The pre-washout visit was completed in either a
hospital or private office. Patients were instructed to com-
plete the remaining assessments at home and return them
by mail in postage pre-paid envelopes to the investigating
site. Patients were assessed at five points in time: baseline
(pre-washout), end of washout, 1 week post-washout,
3 weeks post-washout, and 6 weeks post-washout.
Patients completed, in random order, both the Likert-scaled
and VAS formats of the AUSCAN. Patients also completed
the FIHOA in its original format, as well as in Likert-scaled
and VAS-scaled formats, the order duplicating the previous
AUSCAN order. Finally, patients were asked to complete
the HAQ disability index and HAQ pain scale. The investi-
gational site in Montreal (BH) provided French translations
of the questionnaires.Data analysis
Disease (duration and ACR functional class) and demo-
graphic (age, gender, handedness) profiles are reported
using descriptive statistics. Data were analysed using both
Student’s t-test and standardized response means
(SRM)30. The SRM was calculated as the mean difference
between end of washout and the follow-up assessment
time point (cf. 1, 3 and 6 weeks) values divided by the
standard deviation of this mean difference. We have
expressed responsiveness in terms of the SRM30 rather
than effect size (ES)31 for the following reasons: (a) we
consider the variation in the magnitude of the response
(SRM) to be a more appropriate denominator than the
variation in baseline values (ES) in comparing response
profiles on different instruments, and (b) the reporting of
SRM values is consistent with our previous study on
relative responsiveness in OA outcome measures32 and
facilitates interstudy comparison.ResultsSTUDY 1: VALIDITY AND RELIABILITY STUDYPatients
A total of 57 patients participated in the protocol. How-
ever, seven patients provided incomplete assessments and
were excluded from the analysis, three patients did not
return for the second visit for the following reasons: death in
family, illness and vacation, one patient was ineligible, and
three patients had incomplete AUSCAN questionnaires
(e.g., one page of the physical function questions was left
out of the assessment package). Fifty patients (40F, 10M)
volunteered for the study at two sites; 39 in Canada and 11
in Australia. The mean age was 60.4 years (standard
deviation 7.8, range=41–75) and mean disease duration
(i.e. symptomatic) 9.3 years (standard deviation 8.6,
range=0.75–32). Forty-four were right-handed, five were
left-handed and one was ambidextrous. All fulfilled the
American College of Rheumatology clinical criteria for hand
OA. With respect to American College of Rheumatology
Functional Class26, two were Class I, 43 were Class II, and
five were Class III. The means and standards deviation of
the study group for the AUSCAN and construct validity
measures are illustrated in Table II.Reliability
The test–retest intraclass correlation coefficients for the
AUSCAN LK3.0 were as follows: pain 0.70, stiffness 0.77,
and physical function 0.86; and AUSCAN VA3.0 were pain
0.84, stiffness 0.86, physical function 0.90. Internal consist-
ency, as assessed by Cronbach’s coefficient alpha, was
excellent; for the AUSCAN LK3.0 pain 0.90 at assessment
one and 0.91 at assessment two, physical function 0.94 at
both assessments, AUSCAN VA3.0 pain 0.94 at assess-
ment one and 0.96 at assessment two, and physical
function 0.94 at assessment one and 0.98 at assessment
two.Validity
The construct validity coefficients for AUSCAN LK3.0
and AUSCAN VA3.0 are shown in Table III. Overall, higher
levels of correlation (as expressed by the correlation
coefficients) were noted between both AUSCAN LK3.0 and
AUSCAN VA3.0 scores and measures purported to assess
the same dimension of health than between those
same AUSCAN scores and measures purported to assess
different dimensions of health.STUDY 2: RESPONSIVENESS STUDYPatients
Forty-four patients (38F, 6M) consented to participate in
the study at four sites: 16 at Cabrini Hospital, Melbourne,
Australia, 14 at Centre Hospitalier de l’Universite´ de
Montre´al, Montreal, Quebec, 10 at a private rheumatolo-
gist’s practice, Hamilton, Ontario, and four at London
Health Sciences Centre, London, Ontario, Canada. The
mean age was 59.9 years (standard deviation 8.0, range
44–77) and mean disease duration 9.1 years (standard
deviation 7.2, range=0.3–30). Thirty-six were right-handed,
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not recorded for four patients. All fulfilled the American
College of Rheumatology clinical criteria for hand OA.
With respect to the American College of Rheumatology
Functional Class, eight were in Class I, 17 in Class II, 16 in
Class III, one in Class IV; not recorded for two patients. The
means and standard deviations of the study group for the
AUSCAN and FIHOA are illustrated in Table IV.Table II
Study 1: Means and standard deviations for AUSCAN and construct variables
Variable Mean
assessment 1
Standard
deviation 1
Mean
assessment 2
Standard
deviation 2
AUSCAN Pain LK (0–4) 1.80 0.81 1.76 0.88
AUSCAN Pain VAS (0–100) 45.62 25.20 44.46 28.34
AUSCAN Stiffness LK (0–4) 1.74 1.10 1.52 1.20
AUSCAN Stiffness VAS (0–100) 44.78 32.11 40.96 31.68
AUSCAN Function LK (0–4) 1.82 0.89 1.81 0.96
AUSCAN Function VAS (0–100) 49.55 26.08 48.66 30.11
Grip strength (mm Hg) 188.59 68.05 180.66 63.12
Pinch grip (kg) 5.43 1.96 5.48 2.01
Doyle Index (0–96) 10.22 8.38 11.46 10.60
Patient global pain (0–4) 1.68 0.77 1.68 0.98
Patient global function (0–4) 1.54 0.91 1.52 1.01
Physician global severity (0–4) 1.60 0.64 1.66 0.77
Duration morning stiffness (min) 121.63 339.77 102.35 281.87
FIHOA Original (0–30) 9.88 5.97 9.86 5.62
FIHOA Likert (0–40) 14.88 8.99 13.54 8.53
FIHOA VAS (0–1000) 372.90 246.55 344.44 237.74
HAQ Disability Index (0–3) 1.08 0.77 1.13 0.81
HAQ Pain Scale (0–3) 1.37 0.76 1.50 0.87Table III
Study 1: Construct validity analysis: Pearson correlation coefficients between AUSCAN subscales and validation outcome measures at
assessment one, assessment two
Outcome
Measure
AUSCAN
Pain LK
AUSCAN
Pain VA
AUSCAN
Stiffness LK
AUSCAN
Stiffness VA
AUSCAN
Function LK
AUSCAN
Function VA
Grip strength (mm Hg) −0.25, −0.48 −0.25, −0.43 −0.07, 0.25 −0.21, −0.34 −0.39, −0.60 −0.45, −0.54
Pinch grip (kg) −0.22, −0.33 −0.23, −0.31 −0.08, −0.16 −0.20, −0.18 −0.31, −0.53 −0.36, −0.47
Doyle (0–96) 0.56, 0.44 0.47, 0.56 0.56, 0.55 0.58, 0.62 0.37, 0.47 0.43, 0.50
Patient global pain (0–4) 0.57, 0.70 0.64, 0.79 0.33, 0.54 0.51, 0.63 0.52, 0.61 0.59, 0.69
Patient global function (0–4) 0.52, 0.74 0.65, 0.74 0.49, 0.59 0.54, 0.68 0.72, 0.72 0.74, 0.73
Physician global severity (0–4) 0.63, 0.70 0.65, 0.79 0.37, 0.53 0.50, 0.66 0.63, 0.67 0.68, 0.76
Duration morning stiffness (min)* 0.24, 0.22 0.36, 0.29 0.68, 0.52 0.63, 0.62 0.20, 0.32 0.37, 0.31
FIHOA Original (0–30) 0.67, 0.70 0.74, 0.67 0.45, 0.44 0.54, 0.50 0.78, 0.80 0.86, 0.76
FIHOA Likert (0–40) 0.64, 0.75 0.71, 0.75 0.43, 0.53 0.51, 0.60 0.80, 0.82 0.85, 0.80
FIHOA VAS (0–1000) 0.65, 0.76 0.73, 0.78 0.44, 0.54 0.54, 0.65 0.80, 0.82 0.88, 0.83
HAQ disability index (0–3) 0.52, 0.69 0.61, 0.64 0.53, 0.55 0.62, 0.56 0.65, 0.75 0.68, 0.67
HAQ pain scale (0–3) 0.57, 0.69 0.66, 0.71 0.52, 0.56 0.63, 0.61 0.72, 0.70 0.76, 0.75
Numbers in bold are statistically significant (P≤0.05).
*Spearman correlation coefficient at assessment one, assessment two.Responsiveness
On Likert scaling using Student’s paired t-test, AUSCAN
pain items significantly improved by 1 and 3 weeks post-
washout (P<0.0001), and attained a P-value of 0.0013 by
6 weeks post-washout (Table V). On VA scaling, all items
achieved P values of <0.0001 at 1 and 3 weeks, and
0.0030 at 6 weeks.
On Likert scaling, statistically significant improvement
was noted in morning stiffness at week 1. On VA scaling,morning stiffness significantly improved at all three
follow-up assessments.
On Likert scaling all AUSCAN physical function items
significantly improved by 1 week post-washout (P<0.0001),
by 3 weeks (P=0.0008) and by 6 weeks (P=0.0009). On
VA scaling the respective improvements were 1 week
(P<0.0001), 3 weeks (P=0.0003) and 6 weeks (P=0.0006).
With the FIHOA, the Likert and VA versions significantly
improved by 1 week (P≤0.0368), while at 3 weeks only the
original version significantly improved (P=0.0483), and at
6 weeks the P values did not reach significance
(0.2729≤P≤0.0901).
Standardized response means for the AUSCAN and
FIHOA are reported in Table VI. The values observed for
the AUSCAN pain and function subscales were among the
highest, and for the stiffness of the same order as the
FIHOA. In general, the magnitude of the response detected
was the greatest 1 week after washout. The response
decreased over time (cf. week 1 vs week 6) for both
instruments.
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Study 2: AUSCAN and FIHOA means and standard deviations at each time assessment
Outcome
Measure
Pre-washout Washout Week 1 Week 3 Week 6
Mean S.D. Mean S.D. Mean S.D. Mean S.D. Mean S.D.
AUSCAN Pain LK 1.84 0.72 2.18 0.87 1.69 0.80 1.77 0.89 1.82 0.88
AUSCAN Stiffness LK 1.77 1.03 1.98 1.00 1.67 0.89 1.77 0.89 1.67 1.02
AUSCAN Function LK 1.98 0.71 2.14 0.82 1.76 0.80 1.82 0.81 1.81 0.86
AUSCAN Pain VAS 44.47 24.41 49.91 25.28 40.85 26.31 42.36 24.89 42.92 27.65
AUSCAN Stiffness VAS 42.55 29.88 47.64 30.86 37.77 28.87 37.57 28.19 38.88 30.02
AUSCAN Function VAS 49.39 22.28 52.90 23.46 42.74 25.66 44.68 24.97 43.59 27.17
FIHOA Original 10.39 5.23 11.75 5.21 10.66 4.98 10.91 5.13 10.91 5.30
FIHOA LK 14.75 8.41 16.89 8.87 15.18 8.20 15.68 8.51 16.00 8.90
FIHOA VAS 387.32 217.48 432.14 247.72 379.91 240.53 397.77 244.35 405.58 263.54Table V
Study 2: AUSCAN and FIHOA mean difference, standard deviation and P-value for paired comparisons (t-test)
Outcome
Measure
Washout vs week 1 Washout vs week 3 Washout vs week 6
Mean S.D. P value Mean S.D. P value Mean S.D. P value
AUSCAN Pain LK −0.49 0.67 <0.0001 −0.41 0.61 <0.0001 −0.34 0.64 0.0013
AUSCAN Stiffness LK −0.28 0.88 0.0441 −0.20 0.90 0.1408 −0.30 0.99 0.0515
AUSCAN Function LK −0.37 0.51 <0.0001 −0.31 0.58 0.0008 −0.32 0.60 0.0009
AUSCAN Pain VAS -9.56 12.27 <0.0001 -7.55 11.37 <0.0001 -6.46 13.41 0.0030
AUSCAN Stiffness VAS -8.84 20.57 0.0074 -10.07 20.08 0.0018 -8.07 21.48 0.0179
AUSCAN Function VAS -10.16 11.93 <0.0001 -8.21 14.01 0.0003 -8.97 15.91 0.0006
FIHOA Original -1.09 3.67 0.0552 −0.84 2.74 0.0483 −0.79 2.99 0.0901
FIHOA LK -1.70 5.25 0.0368 -1.20 4.54 0.0857 −0.93 4.81 0.2115
FIHOA VAS -51.23 136.49 0.0167 -33.36 135.92 0.1108 -26.05 153.74 0.2729Table VI
Standardized response means
Outcome
Measure
Week 1
(N=42)
Week 3
(N=44)
Week 6
(N=42)
Weeks 1, 3, 6
Average (N=44)
AUSCAN Pain LK −0.74 −0.67 −0.53 −0.71
AUSCAN Stiffness LK −0.30 −0.23 −0.31 −0.33
AUSCAN Function LK −0.72 −0.54 −0.52 −0.67
AUSCAN Pain VAS −0.79 −0.66 −0.53 −0.84
AUSCAN Stiffness VAS −0.43 −0.50 −0.39 −0.49
AUSCAN Function VAS −0.83 −0.59 −0.55 −0.76
FIHOA Original −0.30 −0.31 −0.27 −0.31
FIHOA LK −0.32 −0.27 −0.19 −0.28
FIHOA VAS −0.37 −0.25 −0.16 −0.27Discussion
In developing a new health status measure for hand OA,
we have been guided by four clinimetric principles
(adequate responsiveness, reliability and validity, and rela-
tive statistical efficiency), and a requirement that it be brief,
simple and capture information using patient self-report.
The end result is a health status measure capable of
measuring clinically-important patient-relevant outcomes.
Our previous experience with the development of the
WOMAC OA Index allowed us to pursue a similar approach
but with greater operational efficiency.
Reliability, as assessed by internal consistency, is a
measure of the extent to which the same or similar values
are assigned to a static phenomenon. Cronbach values at
or above 0.80 are generally accepted as indicative of
adequate reliability. The two versions of the AUSCAN both
meet this requirement. Test–retest reliability is a measure
of stability. Short retest intervals attract the criticism ofmemory effects, while longer periods can be associated
with true change of the underlying condition. In general,
test–retest coefficients decline as a function of time. We
interpret the test–retest data as indicating adequate
stability, the AUSCAN achieving similar values to the
WOMAC Index, based on a 1-week retest interval.
The face validity and content validity of the AUSCAN
Index were assured by the patient-centered development
of the item inventory. Criterion validity is difficult to assess
because of the general lack of gold standards against
which to make the determination. Therefore, extensive use
is made of construct validity testing, a statistico-
judgemental approach in which relationships between
measures are assessed, often using correlation statistics.
For construct validation of the AUSCAN, scores from
several commonly used measures, some observer-
dependent, others observer-independent, were correlated
with AUSCAN scores, with the expectation that, in general,
but not necessarily without exception, correlations between
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greater than between those of different dimensions. It was
also expected that the correlations between measures of
the same dimensions would be at least moderate. The
correlation matrix overall confirms these trends and, there-
fore, the construct validity of both forms of the AUSCAN
Index. As a result, the AUSCAN LK3.0 and AUSCAN VA3.0
have face, content and construct validity.
Responsiveness is a key requirement of an evaluative
measure. The washout retreatment model offers the advan-
tage of observing the responsiveness of the index in a
real-world environment, unaffected by the potential expec-
tation bias that may attend participation in a double-blind
randomized controlled trial, or invasive forms of treatment,
especially surgical intervention. The responsiveness of
both forms of the AUSCAN was confirmed in this real-world
model. In this model the response profile does not show the
continuous improvement often seen in randomized con-
trolled clinical trials of 6 weeks duration, presumably due, in
part, to the absence of expectation. A slowing in the rate of
improvement as a function of time is seen with most
measures of response in this study. Nevertheless, all
subscales, on both types of scaling, achieve statistical
significance at the 1 week or more post-washout time. In
the case of pain and function subscales, highly significant
changes can be detected at all post-washout time points.
Whether the VA stiffness subscale is more responsive than
the Likert stiffness subscale will require further study. This
issue notwithstanding, the Likert-scaled stiffness sub-
scale was capable of detecting statistically significant
improvement during the period of most rapid change.
The relative responsiveness of the FIHOA was of interest
to our group because of its recent appearance. In addition
to comparing the current form of the FIHOA, we were also
interested in evaluating the performance of the FIHOA,
when rescaled to the AUSCAN format. The original form of
the FIHOA appeared less responsive than either the LK3.0
or VA3.0 versions of the AUSCAN. Furthermore, the per-
formance of the FIHOA appeared to decline when rescaled.
We interpret the differential performance of the AUSCAN
and the FIHOA to be attributable to differences in item
content rather than scaling differences, or due to the
self-administration of the FIHOA. Additional evaluations
would be necessary to further address these issues.
Limitations of our study include a focus on right hand
dominant individuals with different configurations of joint
involvement. The performance of the index in left-handed
and ambidextrous individuals, those with unilateral non-
dominant hand involvement , and specific configurations of
joint involvement requires further elucidation. Performance
of the AUSCAN in other research environments has been
partly addressed by several recent publications33–36. In
particular, the responsiveness of the AUSCAN Index has
been confirmed in a placebo controlled double-blind ran-
domized clinical trial of etorocoxib in hand OA patients35,
and alternate language forms of the AUSCAN Index have
been prepared and linguistically validated in English for
U.S.A., Spanish for U.S.A., French for France, German for
Germany, Italian, Dutch and Norwegian.
Strengths of the study include the multinational evalu-
ation of the clinimetric properties of the AUSCAN Index,
which involved two alternate-language translations of the
Index, and two different scaling formats. While we recog-
nize that a small percentage of patients may have concep-
tual difficulties with VA scales, we encountered no such
problems in this study. While this may be attributable to the
study of volunteers rather than a random sample of thegeneral hand population, we believe it is more likely to be
due to the explanation of the VA scale provided to AUSCAN
recipients, on the first page of the Index, prior to the
completion of the questionnaire. It should be noted that we
have not encountered any significant difficulty in 20 years’
experience with the VA version of the WOMAC OA Index1,
which like the AUSCAN Index, has an explanation of how to
use the scale on the first page of the questionnaire.
In summary, using a patient-based approach to item
generation, we have developed a simple, brief, patient
self-reported health status questionnaire for hand OA
studies, and assessed its construct validity, test–retest
reliability, internal consistency, and evaluated its respon-
siveness both when scaled on 5-point Likert-type scaling
and also on 100 mm horizontal visual analogue scal-
ing. The resulting index has acceptable levels of validity,
reliability and appears to be particularly responsive.Acknowledgments
R.-L. Dreiser for providing the FIHOA and scoring system.
Elaine Soucy, MD, Oakville, Canada, Jennifer Flynn,
Summer Student, London, Canada, Maxime Dougados,
MD, Hoˆpital Cochin, Paris, France, Stephen Hall, MD,
Cabrini Hospital, Melbourne, Australia, Ken Muirden, MD,
Royal Melbourne Hospital, Melbourne, Australia, James H.
Roth and R. Richards, Hand and Upper Limb Centre,
St Joseph’s Health Care, London, Canada, Larry W. Stitt,
MSc, Assistant Director, Biostatistical Support Unit, Depart-
ment of Epidemiology and Biostatistics, The University of
Western Ontario, London, Canada.References
1. Bellamy N. Osteoarthritis—an evaluative index for
clinical trials. M.Sc. Thesis. Hamilton: McMaster
University, 1982.
2. Carmines EG, Zeller RA. Reliability and Validity
Assessment. Beverly Hills and London: Sage
Publications 1979.
3. Guion RM. Reliability and validity. In: Standards for
Educational and Psychological Tests. Washington,
DC: American Psychological Association Inc 1974:
25–55.
4. Kirshner B, Guyatt G. A methodological framework for
assessing health indices. J Chron Dis 1985;38(1):
27–36.
5. Hochberg MC, Vignon E, Maheu E. Session 2: Clinical
aspects. Clinical assessment of hand OA. Osteo-
arthritis Cart 2000;8(Suppl A):S38–40. doi:10.1053/
joca.2000.0335.
6. Lequesne MG, Maheu E. Methodology of clinical trials
in hand osteoarthritis: conventional and proposed
tools. Osteoarthritis Cart 2000;8(Suppl A):S64–9.
doi:10.1053/joca.1999.0340.
7. Mejjad O, Maheu E. Therapeutic trials in hand osteo-
arthritis: a critical review. Osteoarthritis Cart
2000;8(Suppl A):S57–63. doi:10.1053/joca.2000.
0339.
8. Altman R, Brandt K, Hochberg M, Moskowitz R,
Bellamy N, Bloch DA, et al. Special Report. Design
and conduct of clinical trials in patients with osteo-
arthritis. Recommendations from a task force of the
Osteoarthritis Research Society. Osteoarthritis Cart
1996;4:217–43.
Osteoarthritis and Cartilage Vol. 10, No. 11 8699. Bellamy N, Kirwan J, Boers M, Brooks P, Strand V,
Tugwell P, et al. Recommendations for a core set of
outcome measures for future phase III clinical trials
in knee, hip, and hand osteoarthritis. Consensus
development at OMERACT III. J Rheumatol
1997;24:799–802.
10. Chevalier X, Mejjad O, Babini S. Session 4: Method-
ology for the assessment of treatments in hand
osteoarthritis. Osteoarthritis Cart 2000;8(Suppl
A):S70–2. doi:10.1053/joca.2000.0341.
11. Bellamy N, Haraoui B, Buchbinder R, Hall S, Muirden
K, Roth J, et al. Development of a disease-specific
health status measure for hand osteoarthritis clinical
trials. 1. Assessment of the symptom dimensionality
(Abstract). Scand J Rheumatol 1996;106(Suppl):5.
12. Bellamy N, Campbell J, Haraoui B, Buchbinder R,
Hobby K, Roth JH, et al. Dimensionality and clinical
importance of pain and disability in hand osteo-
arthritis. Development of the Australian/Canadian
(AUSCAN) Osteoarthritis Hand Index. Osteoarthritis
Cart 2002;11:855–862.
13. Bellamy N, Haraoui B, Buchbinder R, Hall S, Muirden
K, Hobby K, et al. Development of a disease-specific
health status measure for hand osteoarthritis clinical
trials. 2. Assessment of reliability and validity
(Abstract). J Rheumatol 1997;24(7):1425.
14. Bellamy N, Campbell J, Haraoui B, Buchbinder R, Hall
S, Muirden K, et al. Development of the Australian/
Canadian (AUSCAN) Osteoarthritis (OA) Hand Index
(Abstract). Arthritis Rheum 1997;40(9)(Suppl):S110.
15. Bellamy N, Buchanan WW. A preliminary evaluation of
the dimensionaltiy and clinical importance of pain
and disability in osteoarthritis of the hip and knee.
Clin Rheumatol 1986;5(2):231–41.
16. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J,
Stitt LW. Validation study of WOMAC: a health status
instrument for measuring clinically important patient
relevant outcomes to antirheumatic drug therapy in
patients with osteoarthritis of the hip or knee. J
Rheumatol 1988;15:1833–40.
17. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J,
Stitt L. Validation study of WOMAC: a health status
instrument for measuring clinically-important patient-
relevant outcomes following total hip or knee arthro-
plasty in osteoarthritis. J Orthopaedic Rheumatology
1988;1:95–108.
18. Altman RD. Criteria for classification of clinical osteo-
arthritis. J Rheumatol 1991;18(Suppl 27):10–12.
19. Likert R. A technique for measurement of attitudes.
Arch Psychol 1932;140:44–60.
20. Dreiser RL, Maheu E, Guillou GB, Caspard H, Grouin
JM. Validation of an algofunctional index for osteo-
arthritis of the hand. Rev Rheum (English ed.)
1995;62(Suppl 1):43S–53S.
21. Dreiser RL, Maheu E, Guillou GB. Sensitivity to
change of the functional index for hand osteo-
arthritis. Osteoarthritis Cart 2000;8(Suppl A):S25–8.
doi:10.1053/joca.2000.0332.22. Dreiser RL, Maheu E. Inter-rater reproducibility of a
functional index for hand osteoarthritis (HOA)
(Abstract). Osteoarthritis Cart 1997;5(Suppl A):57.
23. Fries JF, Spitz PW, Young DY. The dimensions of
health outcomes: the health assessment question-
naire, disability and pain scales. J Rheumatol
1982;9:789–93.
24. Bellamy N, Wells GA, Campbell J. PARIS Sectogram:
a method for weighting and aggregating the WOMAC
Osteoarthritis Index (Abstract). Osteoarthritis Cart
1994;2(Suppl 1):37.
25. Bellamy N, Buchbinder R, Hall S, Soucy E, Flynn J,
Campbell J. PARIS sectogram: a method for weight-
ing and aggregating the AUSCAN osteoarthritis hand
index. Arthritis Rheum 1998;41(9)(Suppl):S145.
26. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus
T, Wolfe F. The American College of Rheumatology
1991 revised criteria for the classification of global
functional status in rheumatoid arthritis. Arthritis
Rheum 1992;35:498–502.
27. Cronbach LJ. Coefficient alpha and the internal
structure of tests. Psychometrika 1951;16:297–334.
28. Colton T. Regression and correlation. In: Statistics in
Medicine. Boston: Little Brown and Co 1974:
189–217.
29. Rosenbloom D, Brooks P, Bellamy N, Buchanan WW.
Clinical Trials in the Rheumatic Diseases—A
Selected Critical Review. New York: Praeger
Scientific 1985.
30. Liang MH, Fossel AH, Larson MG. Comparisons of five
health status instruments for orthopedic evaluation.
Med Care 1990;28:632–42.
31. Cohen J. Statistical Power Analysis for the Behavioral
Sciences. London: Lawrence Erlbaum Associates
1999:8–14.
32. Bellamy N, Campbell J, Syrotuik J. Comparative study
of self-rating scales in osteoarthritis patients. Curr
Med Res Opin 1999;15:113–19.
33. Bombardier C, Maguire L, Li L, Maetzel A, Jansz G,
The CHAP Team. Characteristics of patients with
osteoarthritis seen by family physicians: results of a
telephone survey in Ontario (Abstract). J Rheumatol
2001;28:1416.
34. Slatkowsky-Christensen B, Bellamy N, Kvien TK.
Examinations of the Norwegian version of
AUSCAN—a disease specific measure of hand
osteoarthritis (OA) (Abstract). Ann Rheum Dis
2001;60(Suppl I):233.
35. Curtis SP, DeTora LM, Leung AT, Malmstrom K, Ko AT,
Sanchez MM, et al. Etoricoxib showed clinically
meaningful efficacy in patients with concomitant hand
osteoarthritis (OA) in phase III clinical development
program (Abstract). Ann Rheum Dis 2002;61
(Suppl I):135.
36. Jones G, Cooley HM, Bellamy N. A cross-sectional
study of the association between Heberden’s nodes,
radiographic osteoarthritis, grip strength, disability.
Osteoarthritis Cart 2001;9:606–11.
